Data powered by Alphabet Inc.
Eris Lifesciences
ERIS
₹ 1,071.02
₹ 1.07
0.10%
Eris Lifesciences Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 49,428 |
| Weekly | 6.66% | 4,29,804 |
| Monthly | 3.04% | 65,32,789 |
Eris Lifesciences Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| ERIS | - | 6.66% | 3.04% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
*Avg of index constituents
Eris Lifesciences Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| ERIS | 22.76 | 4.90 | 17.02 | 23.62 | 25.86 | 0.94 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
*Avg of index constituents
Eris Lifesciences Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 10.40% | 16.63% | 23.62% | 25.86% |
| FY '20-21 | 10.76% | 20.07% | 24.61% | 27.36% |
| FY '19-20 | 11.58% | 1.95% | 24.02% | 25.09% |
Eris Lifesciences Shareholding Pattern
Promoters : 52.66%
FII : 13.31%
DII : 10.5%
Public : 23.52%
Others : 0.01%
Eris Lifesciences Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 1,281.39 | 796.85 | 512.08 | 411.49 |
| FY '20-21 | 1,160.35 | 736.24 | 433.46 | 352.87 |
| FY '19-20 | 1,047.14 | 685.72 | 377.17 | 293.89 |
All values are in crores
Eris Lifesciences Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| ERIS | 1,281.39 | 796.85 | 512.08 | 411.49 |
| GRANULES | 3,501.68 | 2,818.85 | 701 | 399.64 |
| NATCOPHARM | 1,856.30 | 1,618.05 | 335.05 | 154.55 |
All values are in crores
Eris Lifesciences Share Price
Eris Lifesciences Limited is an Indian company primarily engaged in the production and distribution of pharmaceutical products. The company's manufacturing facility is located in Guwahati, Assam. Its therapeutic areas include oral diabetes, cardiac, pain/analgesic, gynecology, gastrointestinal, central nervous system (CNS) and vitamins, minerals and nutrients (VMN). The company's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cybex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The company's 100% subsidiaries are Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.